$2.9 B

LGND Mkt cap, 14-Dec-2018

$45.7 M

Ligand Pharmaceuticals Revenue Q3, 2018
Ligand Pharmaceuticals Gross profit (Q3, 2018)44.2 M
Ligand Pharmaceuticals Gross profit margin (Q3, 2018), %96.8%
Ligand Pharmaceuticals Net income (Q3, 2018)67.4 M
Ligand Pharmaceuticals EBIT (Q3, 2018)23.4 M
Ligand Pharmaceuticals Cash, 30-Sep-2018115.6 M

Ligand Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

49.0m64.5m71.9m109.0m141.1m

Revenue growth, %

32%11%52%

Cost of goods sold

5.6m5.4m

Gross profit

103.4m135.7m

Gross profit Margin, %

95%96%

R&D expense

9.3m13.4m21.2m26.9m

General and administrative expense

18.0m24.4m26.6m28.7m

Operating expense total

34.0m44.6m65.1m73.0m

Depreciation and amortization

10.6m12.1m

EBIT

14.9m19.6m27.3m(2.4m)12.6m

EBIT margin, %

31%30%38%(2%)9%

Interest expense

2.1m4.9m11.8m12.2m11.4m

Income tax expense

(10.3m)(44.7m)

Net Income

11.4m10.9m257.3m(1.6m)12.6m

Ligand Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

11.6m160.2m97.4m18.8m20.6m

Accounts Receivable

2.2m12.6m6.2m14.7m25.6m

Inventories

1.4m269.0k1.6m1.9m4.4m

Current Assets

24.9m185.2m215.6m163.1m237.0m

PP&E

867.0k486.0k372.0k1.8m4.2m

Goodwill

12.2m12.2m12.2m72.2m86.0m

Total Assets

104.7m258.0m533.9m601.6m671.0m

Accounts Payable

4.0m7.7m4.1m2.7m2.3m

Short-term debt

9.1m

Current Liabilities

28.9m22.8m20.8m227.1m238.9m

Long-term debt

13.4m

Total Debt

28.3m

Total Liabilities

55.1m229.5m230.7m252.4m

Additional Paid-in Capital

718.0m680.7m701.5m769.7m798.2m

Retained Earnings

(671.3m)(659.3m)(402.0m)(431.1m)(400.9m)

Total Equity

24.4m304.4m341.3m399.8m

Debt to Assets Ratio

0.3 x

Financial Leverage

10.6 x1.8 x1.8 x1.7 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

3.3m13.0m14.5m180.7m165.8m108.2m93.8m31.3m61.4m86.6m10.6m60.2m32.7m51.0m151.5m115.6m

Accounts Receivable

5.5m4.7m3.1m5.8m7.4m5.5m5.5m11.8m10.0m6.6m7.1m13.5m12.8m37.1m42.0m47.0m

Inventories

1.8m1.9m817.0k1.1m2.8m802.0k1.2m1.8m3.8m4.0m7.6m6.8m5.0m10.5m9.5m8.1m

Current Assets

16.6m33.4m28.6m198.5m191.7m196.7m210.3m133.1m126.6m140.7m174.7m197.2m224.2m349.1m1.5b1.7b

PP&E

834.0k690.0k619.0k551.0k440.0k405.0k355.0k567.0k1.2m1.8m1.9m1.9m3.5m4.1m4.2m4.4m

Goodwill

12.2m12.2m12.2m12.2m12.2m12.2m12.2m73.0m72.4m72.4m72.2m72.2m72.2m86.0m86.0m86.0m

Total Assets

101.7m105.5m99.8m272.3m263.2m304.8m521.7m613.4m616.8m600.9m629.7m640.0m662.3m754.7m1.9b2.1b

Accounts Payable

4.3m3.7m5.1m4.9m7.4m2.7m3.1m2.7m2.3m2.8m6.5m1.8m3.6m3.4m2.7m1.6m

Short-term debt

12.4m5.8m2.7m

Current Liabilities

32.5m21.0m18.6m18.4m18.2m17.9m16.3m12.2m220.3m226.1m227.0m225.8m231.7m247.0m632.9m793.3m

Long-term debt

193.6m200.6m203.0m204.7m

Total Debt

12.4m5.8m2.7m193.6m200.6m203.0m204.7m

Total Liabilities

56.9m40.5m36.8m229.5m230.8m235.7m229.5m221.4m224.9m230.5m230.9m230.6m237.6m257.5m1.2b1.4b

Additional Paid-in Capital

758.1m723.3m726.8m707.2m684.4m692.8m697.1m783.9m789.3m762.6m777.1m784.4m793.7m808.8m874.2m883.5m

Retained Earnings

(673.2m)(669.2m)(667.6m)(666.4m)(658.6m)(635.0m)(410.5m)(395.4m)(401.2m)(428.0m)(408.4m)(402.3m)(393.9m)(327.4m)(254.2m)(183.9m)

Total Equity

44.8m65.0m371.8m385.1m403.2m481.1m619.8m699.5m

Debt to Equity Ratio

0.3 x0.1 x

Debt to Assets Ratio

0.1 x0.1 x0 x0.3 x

Financial Leverage

2.3 x1.6 x1.7 x1.7 x1.6 x1.6 x3 x3 x

Ligand Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

11.4m10.9m254.9m(1.6m)12.6m

Depreciation and Amortization

2.7m2.7m2.6m11.3m11.7m

Accounts Receivable

2.4m(10.0m)6.5m(8.5m)(8.4m)

Inventories

646.0k4.4m(401.0k)(244.0k)(843.0k)

Accounts Payable

(2.8m)(4.0m)(2.4m)(1.7m)

Cash From Operating Activities

20.7m20.6m41.7m63.0m93.6m

Purchases of PP&E

(6.0k)(93.0k)(1.8m)(2.2m)

Cash From Investing Activities

(5.0m)(2.0m)(112.9m)(143.2m)(84.2m)

Long-term Borrowings

(19.6m)(9.4m)

Cash From Financing Activities

(16.5m)130.0m8.4m1.5m(7.5m)

Interest Paid

1.8m494.0k1.8m1.8m1.8m

Income Taxes Paid

26.0k18.0k28.0k38.0k157.0k

Ligand Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

3 x
Report incorrect company information

Ligand Pharmaceuticals Employee Rating

3.01 votes
Culture & Values
N/A
Work/Life Balance
3.0
Senior Management
3.5
Salary & Benefits
3.0
Career Opportunities
3.0
Source